Meanwhile, U.S. drug pricing and reimbursement was an issue for 39%, while 32% of respondents to the survey, carried out by the investment bank Lazard, cited FDA regulatory uncertainty. Compared to ...
FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with ...
See why Scholar Rock Holding Corporation remains a Strong Buy despite regulatory setbacks, with key catalysts ahead and ...
4don MSN
Genetic model reveals a form of calcium release is unnecessary for normal muscle contraction
The mechanism of skeletal muscle contraction is a process that relies on calcium signaling. However, the physiological role ...
University of Cincinnati researchers, led by LaShan Hendrix, are studying ways to reverse arterial calcification at the ...
After menopause, women with MS show accelerated loss of volume in brain structures associated with memory, attention, and problem-solving.
In its rejection letter, the FDA flagged problems at a third-party fill-finish site owned by Novo Nordisk. Issues at this ...
The U.S. Food and Drug Administration's so-called complete response letter is related to issues identified during a routine ...
BACKGROUND: PYGM (muscle glycogen phosphorylase), the rate-limiting enzyme in glycogenolysis, plays an indispensable role in maintaining cardiac energy metabolism. However, the role of PYGM in the ...
Asianet Newsable on MSN
Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues
The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback